Advancing Care in Achondroplasia: From Diagnosis to Clinical Evidence and Patient-Centered Care - Episode 5
Deciding When to Start Treatment in Achondroplasia
Earlier intervention may offer opportunities to influence skeletal development, but treatment timing must be weighed against uncertainty, treatment burden, and the needs of individual families.
In this episode, “Deciding When to Start Treatment in Achondroplasia,” the panelists explore the timing of intervention and the expanding pharmacologic treatment landscape in achondroplasia. The discussion begins with the currently available CNP-pathway therapies and how they counteract excessive FGFR3 signaling. The panel explains that CNP signaling through NPR-B can help offset the inhibitory effect of overactive FGFR3 on chondrocyte proliferation, providing a biologic rationale for targeted treatment during periods of active skeletal growth.
The experts then consider whether treatment should begin as early as possible. Children with achondroplasia diverge from typical growth trajectories early in life, and emerging data suggest the possibility that earlier intervention may eventually affect outcomes beyond height. Potential areas of interest include spinal development, kyphosis, scoliosis, foramen magnum anatomy, and other disease-related complications, although the panel stresses that much of this evidence remains preliminary.
The conversation also highlights an important counterpoint: long-term injections can create practical, emotional, and psychosocial burdens for children and caregivers. The panel cautions against assuming that every family should make the same decision and emphasizes the importance of presenting the available evidence honestly. Ultimately, treatment timing should reflect a shared decision-making process that balances potential long-term benefit, uncertainty, family priorities, and the burden of ongoing therapy.
The next episode, “Long-Term Outcomes With CNP Analogue Therapy in Achondroplasia,” will focus on clinical data with daily CNP analogue therapy. The panel will review growth, safety, and emerging observations in infants and children younger than 5 years of age.
